VR Adviser LLC grew its holdings in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) by 41.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,046,414 shares of the company's stock after purchasing an additional 1,480,573 shares during the period. enGene makes up 2.3% of VR Adviser LLC's portfolio, making the stock its 16th biggest position. VR Adviser LLC owned about 11.41% of enGene worth $33,559,000 at the end of the most recent quarter.
A number of other hedge funds also recently modified their holdings of ENGN. Vontobel Holding Ltd. acquired a new position in enGene during the fourth quarter worth $69,000. Jane Street Group LLC acquired a new position in enGene during the fourth quarter worth $93,000. Toronto Dominion Bank acquired a new position in enGene during the fourth quarter worth $97,000. Cubist Systematic Strategies LLC increased its position in enGene by 15.7% during the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock worth $102,000 after buying an additional 2,080 shares during the last quarter. Finally, Corton Capital Inc. acquired a new position in enGene during the fourth quarter worth $157,000. Hedge funds and other institutional investors own 64.16% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms have commented on ENGN. JMP Securities reissued a "market outperform" rating and set a $18.00 target price on shares of enGene in a research report on Tuesday, April 29th. Morgan Stanley decreased their price target on shares of enGene from $37.00 to $34.00 and set an "overweight" rating for the company in a report on Tuesday, March 11th. Piper Sandler assumed coverage on shares of enGene in a report on Tuesday, February 18th. They set an "overweight" rating and a $26.00 price target for the company. HC Wainwright restated a "buy" rating and set a $25.00 price target on shares of enGene in a report on Tuesday, March 11th. Finally, UBS Group cut shares of enGene from a "buy" rating to a "neutral" rating and decreased their price target for the company from $34.00 to $7.00 in a report on Friday, February 14th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $23.29.
View Our Latest Stock Analysis on enGene
enGene Stock Performance
ENGN stock traded down $0.05 during mid-day trading on Friday, reaching $4.24. 45,475 shares of the stock traded hands, compared to its average volume of 133,060. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. The business has a 50-day moving average of $4.07 and a two-hundred day moving average of $5.92. enGene Holdings Inc. has a 52 week low of $2.65 and a 52 week high of $12.80. The firm has a market capitalization of $216.15 million, a PE ratio of -7.31 and a beta of -0.36.
About enGene
(
Free Report)
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
See Also
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
